Skip to main content
Equibles
HALO logo

HALO · Halozyme Therapeutics, Inc. · Metrics

Track HALO — free

Use HALO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HALO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$124.37 +1.87 (+1.53%) At close · Oct 20
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$14.12B
Shares
113.50M
Volume · Oct 20 2.2M Avg daily vol (3M) 2.24M

HALO metrics

111 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$124.37
Market cap
$14.12B

Price action

20 metrics
Price change (1W)
+13.5%
Price change (30D)
+11.6%
Price change (3M)
+58.2%
Price change (6M)
+81.8%
Price change (YTD)
+84.8%
Price change (1Y)
+87.1%
Trailing year
Price change (5Y)
+225.8%
52-week high
$124.37
52-week low
$61.63
Change from 52-week high
+0.0%
Change from 52-week low
+101.8%
Annualized volatility
37.5%
Annualized volatility (3M)
48.4%
Beta
0.5
RSI (14D)
73.1
Price vs SMA 50
+13.3%
Price vs SMA 200
+53.2%
Avg volume (3M)
2.24M
Relative volume
1.0
Average dollar volume
$236.70M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
113.50M

Valuation

12 metrics
P / E (TTM)
36.4
Trailing earnings · reciprocal yield 2.7%
PEG ratio
0.8
EV / revenue
9.5×
reciprocal yield 10.5%
EV / EBITDA
26.0×
reciprocal yield 3.9%
EV / EBIT
26.6×
reciprocal yield 3.8%
P / sales
8.4×
reciprocal yield 12.0%
P / book
96.9
reciprocal yield 1.0%
FCF yield
5.8%
TTM · current market cap
Buyback yield
2.7%
P / FCF
17.2
reciprocal yield 5.8%
P / operating cash flow
17.0
reciprocal yield 5.9%
Earnings yield
3.0%

Historical valuation

8 metrics
P / E historical average (3Y)
19.7×
reciprocal yield 5.1%
P / E historical average (5Y)
20.3×
reciprocal yield 4.9%
EV / revenue historical average (3Y)
7.8×
reciprocal yield 12.9%
EV / revenue historical average (5Y)
9.9×
reciprocal yield 10.1%
EV / EBIT historical average (3Y)
17.7×
reciprocal yield 5.6%
EV / EBIT historical average (5Y)
20.2×
reciprocal yield 5.0%
EV / EBITDA historical average (3Y)
17.3×
reciprocal yield 5.8%
EV / EBITDA historical average (5Y)
19.7×
reciprocal yield 5.1%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
2.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
83.6%
Operating margin
35.9%
Trailing 12 months
Net margin
24.9%
Gross profit (TTM)
$12.62M
Operating profit (TTM)
$597.20M
Net income (TTM)
$413.60M
Trailing 12 months
Diluted EPS (TTM)
$3.42
FCF margin
48.5%
Effective tax rate
29.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$13.62
Gross profit per diluted share (TTM)
$0.09
Operating profit per diluted share (TTM)
$4.90
EBITDA per diluted share (TTM)
$5.02
Net income per diluted share (TTM)
$3.39
Operating cash flow per diluted share (TTM)
$6.70
Free cash flow per diluted share (TTM)
$6.60
Capital expenditures per diluted share (TTM)
$0.10
R&D per diluted share (TTM)
$0.84
Stock compensation per diluted share (TTM)
$0.52
Book value per share
$0.41

Growth

11 metrics
Revenue growth YoY
+47.7%
Year over year
Net income growth YoY
+39.2%
Revenue (TTM)
$1.66B
Trailing 12 months
EPS growth YoY
+42.9%
Shares change YoY
-2.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+28.4%
Revenue CAGR (5Y)
+39.2%
EPS CAGR (3Y)
+21.1%
EPS CAGR (5Y)
+23.0%
FCF CAGR (3Y)
+39.9%
FCF CAGR (5Y)
+64.8%

Quality

14 metrics
Return on equity
288.1%
Return on assets
16.0%
Debt / equity
15.0
Current ratio
2.7
EBITDA (TTM)
$611.92M
Free cash flow (TTM)
$806.22M
Quick ratio
2.3
Interest coverage
29.4
Net debt / EBITDA
3.2
Return on invested capital
19.9%
Trailing 12 months
Net cash
−$1.98B
Latest balance sheet
Cash & equivalents
$163.14M
Total assets
$2.58B
Total debt
$2.15B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$818.60M
Capital expenditures (TTM)
$12.37M
R&D (TTM)
$102.37M
SG&A (TTM)
$238.00M
Stock compensation (TTM)
$63.07M
R&D / revenue
6.2%
Stock compensation / revenue
3.8%

Ownership (13F)

9 metrics
13F filers
677
13F filer change QoQ
+38
Institutional ownership
109.3%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.7%
Holder tenure
15.9
Price vs estimated holder cost
+33.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
26.0%

Short interest

3 metrics
Short interest
13.5%
Latest settlement · 4.5 days to cover
Days to cover
4.5d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$22.10M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1159036 CUSIP 40637H109 13F (30d) 121 filings 118 filers Visit website Investor relations